2011
DOI: 10.1590/s0066-782x2011005000110
|View full text |Cite
|
Sign up to set email alerts
|

Associação de níveis plasmáticos de PAI-1 e polimorfismo 4G/5G em pacientes com doença arterial coronariana

Abstract: Background: Type-1 plasminogen activator inhibitor (PAI-1) 4G/5G polymorphism may influence the PAI-1 expression. High plasma levels of PAI-1 are associated with coronary artery disease (CAD).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(8 citation statements)
references
References 20 publications
0
8
0
Order By: Relevance
“…Interestingly, this finding conflicts with the results of our research; the discrepancy could be due to differences in the ethnic group or sample size used. On the other hand, the Turkish postmenopausal women exhibited only osteoporosis [35], whereas our study participants exhibited symptoms of greater severity, such as compound fracture due to osteoporosis; this could also be the reason for the discrepancy between the results of the two studies. There are several limitations to our study.…”
Section: Discussionmentioning
confidence: 65%
See 1 more Smart Citation
“…Interestingly, this finding conflicts with the results of our research; the discrepancy could be due to differences in the ethnic group or sample size used. On the other hand, the Turkish postmenopausal women exhibited only osteoporosis [35], whereas our study participants exhibited symptoms of greater severity, such as compound fracture due to osteoporosis; this could also be the reason for the discrepancy between the results of the two studies. There are several limitations to our study.…”
Section: Discussionmentioning
confidence: 65%
“…First, serum PAI-1 concentrations were not examined in our study population. Previous studies have evaluated the contribution of each PAI-1 polymorphism to serum PAI-1 expression [35,36,37]. Second, functional studies for PAI-1 SNP were not performed to elucidate OVCF-related pathogenesis.…”
Section: Discussionmentioning
confidence: 99%
“…As indicated in some previous studies, 4G/4G genotype or 4G allele may be a risk factor for development of disease,[121314] whereas others proposed a protective role for 4G/4G genotype or 4G allele against symptoms. [151617] Also, in our previous study we showed that FMF patients carrying 5G/5G genotype are more susceptible to the progression of disease symptoms.…”
Section: Discussionmentioning
confidence: 99%
“…The association of PAI-1 gene polymorphism with several diseases such as Familial Mediterranean Fever,[11] Type 2 Diabetes,[12] Acute Myocardial Infarction,[13] and Coronary Artery Disease[14] has been investigated. As indicated in some previous studies, 4G/4G genotype or 4G allele may be a risk factor for development of disease,[121314] whereas others proposed a protective role for 4G/4G genotype or 4G allele against symptoms.…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, thromboxane A2 (TXA2) and thromboxane B2 (TXB2) have aggregating action, 36 as well as the inhibitor of plasminogen activator type 1 (PAI-1) that can promote the permanence of the fibrin clot inhibiting fibrinolysis. 38 Methylxanthines, such as caffeine, are non-selective blockers of the adenosine receptor 33 and act especially on the A2A receptor, specifically expressed in platelets. 33,39 Regarding platelet aggregation, in vitro studies indicate caffeine as a phosphodiesterase blocker, which blocks the conversion of cAMP into 5-AMP, increasing cAMP, with consequent inhibition of platelet aggregation.…”
Section: Introductionmentioning
confidence: 99%